Cubicin Meets Phase 2 Safety Study Objectives: Cubist Pharma

Cubicin is approved in the US and many other markets as therapy for Staphylococcus aureus bloodstream infections (bacteremia), including right-sided endocarditis caused by methicillin-resistant S aureus (MRSA), and complicated skin infections caused by certain gram-positive bacteria, including MRSA.

Cubicin Phase 2 study is a randomised controlled Phase 2 trial studying anti-infective therapy in the setting of 2-stage surgery for the replacement of infected prosthetic hip or knee joints.

Cubist Pharma’s Cubicin Phase 2 study evaluated Cubicin at doses of 6 and 8mg/kg in comparision with standard of care (vancomycin, teicoplanin or semi-synthetic penicillins) administered for approximately 6 weeks following surgery.

Primary objective of the study involved evaluating the safety and tolerability of Cubicin at the two doses studied. The clinical response rate for Cubicin at both doses studied was numerically higher than comparator at the Test of Cure (TOC) visit.

Cubist Pharmaceuticals is a biopharmaceutical company into the research, development, and commercialisation of pharmaceutical products that address unmet medical needs in the acute care environment.